CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
Year-over-year revenue growth rate
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | -97.53% |
| Q4 2024 | 0.00% |
| Q3 2024 | -100.00% |
| Q2 2024 | 2.58% |
| Q1 2024 | -99.75% |
| Q4 2023 | 0.00% |
| Q3 2023 | -100.00% |
| Q2 2023 | -30.00% |
| Q1 2023 | 1666566.67% |
| Q4 2022 | -93.62% |
| Q3 2022 | -40.51% |
| Q2 2022 | -11.24% |
| Q1 2022 | -98.62% |
| Q4 2021 | 3820.67% |
| Q3 2021 | -99.96% |
| Q2 2021 | 445544.55% |
| Q1 2021 | -45.41% |
| Q4 2020 | 150.00% |
| Q3 2020 | 236.36% |
| Q2 2020 | -71.97% |
| Q1 2020 | -99.80% |
| Q4 2019 | -63.66% |
| Q3 2019 | 66544.03% |
| Q2 2019 | -3.05% |
| Q1 2019 | 185.22% |
| Q4 2018 | -79.57% |
| Q3 2018 | -48.25% |
| Q2 2018 | -19.88% |
| Q1 2018 | -95.80% |
| Q4 2017 | 1254.21% |
| Q3 2017 | -33.36% |
| Q2 2017 | 32.52% |
| Q1 2017 | 15.32% |
| Q4 2016 | 51.32% |
| Q3 2016 | 94.84% |
| Q2 2016 | 67.02% |
| Q1 2016 | 92.71% |
| Q4 2015 | 0.00% |